4-Nitro-2-methoxy-ethylbenzol | 90610-19-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Nitro-2-methoxy-ethylbenzol
• 英文别名: 2-ethyl-5-nitro-anisole；2-Aethyl-5-nitro-anisol；1-ethyl-2-methoxy-4-nitrobenzene
• CAS: 90610-19-8
• 化学式: C₉H₁₁NO₃
• 分子量: 181.191
• InChiKey: ZXPPNSLDISRCTN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-Nitro-2-methoxy-ethylbenzol 在 二硫化碳 、 magnesium(II) nitrate 、 potassium permanganate 、 aluminum tri-bromide 作用下， 生成 2-羟基-4-硝基苯乙酮
  参考文献：
  名称：

  Kao; Pan, Huaxue Xuebao/Acta Chimica Sinica, 1958, vol. 24, p. 240,249

  摘要：

  DOI：
• 作为产物：
  描述：

  2-乙基-5-硝基苯酚 在 sodium hydroxide 、 硫酸二甲酯 作用下， 生成 4-Nitro-2-methoxy-ethylbenzol
  参考文献：
  名称：

  Kao; Pan, Scientia Sinica (English Edition), 1958, vol. 7, p. 1043,1048

  摘要：

  DOI：

文献信息

• Non-basic melanin concentrating hormone receptor-1 antagonists
  申请人：Washburn N. William

  公开号：US20070093509A1

  公开（公告）日：2007-04-26

  The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

  本申请提供了按照公式I提供的化合物，包括所有立体异构体、溶剂合物、前药和药学上可接受的形式。此外，本申请提供了含有至少一种按照公式I的化合物和可选的至少一种额外治疗剂的制药组合物。最后，本申请提供了通过给予按照公式I的化合物的治疗有效剂量来治疗患有MCHR-1调节的疾病或疾病，例如肥胖症、糖尿病、抑郁症或焦虑症的患者的方法。
• Phosphodiesterase 10 inhibitors
  申请人：Arrington Mark P.

  公开号：US20090099175A1

  公开（公告）日：2009-04-16

  The present invention if directed to certain cinnoline compounds that are PDE10 inhibitors, pharmaceutical compositions containing such compounds and processes for preparing such compounds. The invention is also directed to methods of treating diseases mediated by PDE10 enzyme, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

  本发明涉及某些具有PDE10抑制剂作用的茚啉化合物，包括含有这些化合物的制药组合物和制备这些化合物的方法。该发明还涉及通过PDE10酶介导的疾病的治疗方法，例如肥胖症、非胰岛素依赖性糖尿病、精神分裂症、双相情感障碍、强迫症等。
• CATHEPSIN S INHIBITORS
  申请人：Lin Chun-Cheng

  公开号：US20110166141A1

  公开（公告）日：2011-07-07

  Cathepsin S inhibitors having formula (I), (II), (III) or (IV) as shown in the specification. These inhibitors can be used to treat cancer and autoimmune/inflammatory diseases.

  具有(I)、(II)、(III)或(IV)公式的卡特普西林S抑制剂，如规范所示。这些抑制剂可用于治疗癌症和自身免疫/炎症性疾病。
• Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
  申请人：Washburn William N.

  公开号：US08618115B2

  公开（公告）日：2013-12-31

  The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

  本申请提供了公式I所示的化合物，包括所有立体异构体、溶剂化物、前药和药学上可接受的形式。此外，本申请还提供了含有至少一种公式I化合物和可选的至少一种其他治疗剂的药物组合物。最后，本申请提供了通过给患有MCHR-1调节性疾病或疾病的患者以公式I化合物的治疗有效剂量来治疗患者的方法，例如肥胖症、糖尿病、抑郁症或焦虑症。
• Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
  申请人：Bristol-Myers Squibb Company

  公开号：EP2298776A1

  公开（公告）日：2011-03-23

  The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula 1.

  本申请提供了根据式 I 的化合物，包括其所有立体异构体、溶解物、原药和药学上可接受的形式。此外，本申请还提供了含有至少一种根据式 I 的化合物和可选的至少一种额外治疗剂的药物组合物。最后，本申请提供了通过施用治疗有效剂量的根据式 1 的化合物来治疗患有 MCHR-1 调节的疾病或紊乱的患者的方法，例如肥胖症、糖尿病、抑郁症或焦虑症。